Revolution Medicines (United States)

Recent papers from Revolution Medicines (United States)

1. Discovery of RMC-0708, an Oral, Bis-Macrocyclic, RAS(ON) Q61H-Selective, Noncovalent, Tri-Complex InhibitorJournal of Medicinal Chemistry · 2026
2. Discovery of Zoldonrasib (RMC-9805), a Potent and Orally Bioavailable RAS(ON) G12D-Selective, Covalent, Tri-Complex Inhibitor for the Treatment of Patients with RAS G12D-Addicted CancersJournal of Medicinal Chemistry · 2026
3. Decoding personal and population variability in the human multiome2026
4. Daraxonrasib for Previously Treated RAS -Mutant Non–Small-Cell Lung CancerNew England Journal of Medicine · 2026
5. Acquired resistance to the RAS(ON) multi-selective inhibitor daraxonrasib guides rational combination therapy strategies in pancreatic cancerNature Medicine · 2026
6. Concurrent AXL Inhibition Enhances RAS and ERK Inhibitor Efficacy in KRAS -mutant Pancreatic and Lung Cancer2026
7. Ersodetug for Refractory Hypoglycemia Due to Malignant Insulin-Secreting TumorsThe Journal of Clinical Endocrinology & Metabolism · 2026
8. “I'm Doing My Part, Why Aren't You Doing Yours?”: A Qualitative Exploration of the Expanded Child Tax Credit Among Mothers with Young ChildrenJournal of Health Politics Policy and Law · 2026
9. Distinct ERK and PI3K dependencies mediate a heterogeneous response to RAS(ON) inhibition in KRAS-mutant colorectal cancerCell Reports · 2026
10. Field-Based Compressor Performance Validation: Engineering Portable Test Systems for Real-World Accuracy2026
11. Daraxonrasib, a RAS(ON) multi-selective inhibitor vs chemotherapy in previously treated metastatic pancreatic adenocarcinoma (mPDAC): Primary and final analysis from the phase 3 RASolute 302 study.Journal of Clinical Oncology · 2026
12. Intratumoral Regulatory T cell Ablation Mediates Tumor Control Systemically without AutoimmunityCancer Research · 2026
13. Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic CancerNew England Journal of Medicine · 2026
14. Patient characteristics, treatment patterns, and survival in a metastatic pancreatic adenocarcinoma US patient population.Journal of Clinical Oncology · 2026
15. Safety and efficacy of daraxonrasib monotherapy as later-line (3L+) treatment for patients (pts) with metastatic pancreatic adenocarcinoma (PDAC).Journal of Clinical Oncology · 2026
16. Systemic anticancer therapy in patients with de novo metastatic pancreatic adenocarcinoma: A real-world analysis.Journal of Clinical Oncology · 2026
17. HRDetect in Tubo-ovarian Carcinoma: Stratification and Therapeutic ImplicationsClinical Cancer Research · 2026
18. Genetic Drivers of Sensitivity or Resistance to RAS(ON) Multi-Selective Inhibitors in NRAS-Mutated MelanomaCancer Research · 2026
19. Abstract CT021: Preliminary safety and clinical activity of zoldonrasib (RMC-9805), an oral, RAS(ON) G12D-selective, tri-complex inhibitor in patients with previously treated KRAS G12D non-small cell lung cancer (NSCLC)Cancer Research · 2026
20. Disrupted molecular glue complex drives RAS inhibitor resistanceCell · 2026